KP.2-based monovalent mRNA vaccines robustly boost antibody responses to SARS-CoV-2. Wang Q, Mellis IA, Wu M, Bowen A, et al. Lancet Infect Dis 2025 Feb 4:S1473-3099(25)00058.

Read + Share

Amedeo Smart

Independent Medical Education

Wang Q, Mellis IA, Wu M, Bowen A, et al. KP.2-based monovalent mRNA vaccines robustly boost antibody responses to SARS-CoV-2. Lancet Infect Dis 2025 Feb 4:S1473-3099(25)00058.
PMID: 39919777